The Price of Protection: Value, Burden, and Fairness

The health effect of an influenza PHSM is only one part of the policy judgment. This chapter examines what happens when the same measures are evaluated for costs, opportunity costs, distribution and rights. The distinction matters because a measure can reduce transmission yet fail to offer good value under a particular threshold, while a modest and inexpensive measure can become valuable as part of a package. The reader’s task is to keep those judgments connected without collapsing them into one number.

A health effect is not a value judgment

Epidemiological effectiveness asks whether a measure changes transmission or health outcomes: infections, hospitalizations, deaths, peak demand or the timing of an epidemic. Cost-effectiveness asks whether the health gains are worth the resources used under a specified perspective and threshold. Cost-benefit analysis may express health and non-health consequences in monetary terms. None of these is simply a more complete version of the others. They answer different questions and count different consequences.

The perspective determines whose costs and benefits are visible. A health-system analysis may count programme costs and avoided medical care while excluding lost wages, childcare or school disruption. A societal analysis may include those wider effects, but it still requires assumptions about how to value them. A school closure can lower transmission and perhaps reduce hospital demand, while also removing education, school meals and childcare and reducing parents’ ability to work. Whether the policy is worth adopting can change when those consequences are included.

The threshold matters as well. A cost-effectiveness result is not a natural property of an intervention like its mechanism of action. It depends on what a decision-maker is willing to pay for a health gain, which outcomes are valued, the time horizon and the alternative uses of the same resources. A strategy can be judged favorably in a severe pandemic when avoiding deaths and health-system collapse has high value, yet unfavorably during a lower-severity period when disruption dominates the expected health benefit. The direction of the judgment can change without anyone having discovered a different biology.

The recent systematic review of economic evaluations illustrates this conditionality. It included 33 full evaluations, 13 concerning influenza and 20 concerning COVID-19. The studies differed in disease severity, timing, duration, intervention, model, perspective and outcome. Because of that heterogeneity, the review synthesized patterns narratively rather than producing one pooled cost-effectiveness estimate.

School closures were the most frequently evaluated measure and were generally not cost effective as standalone interventions, except in severe pandemics or selected short-term conditions. When closures were combined with other measures, vaccination or antivirals, results became mixed rather than uniformly favorable. That pattern is not a verdict that school closure can never be justified. It says that the health benefit has to be large enough, early enough or otherwise distinctive enough to compensate for education, childcare, workforce and household costs.

Workplace and business measures showed a similar dependence on scenario. They were often evaluated as part of larger strategies, making their independent contribution difficult to isolate. Some combinations were cost effective only under high-severity influenza assumptions; others were unfavorable.